[go: up one dir, main page]

AR111032A1 - Composición líquida que contiene pradofloxacina - Google Patents

Composición líquida que contiene pradofloxacina

Info

Publication number
AR111032A1
AR111032A1 ARP180100319A ARP180100319A AR111032A1 AR 111032 A1 AR111032 A1 AR 111032A1 AR P180100319 A ARP180100319 A AR P180100319A AR P180100319 A ARP180100319 A AR P180100319A AR 111032 A1 AR111032 A1 AR 111032A1
Authority
AR
Argentina
Prior art keywords
pradofloxacine
composition containing
liquid composition
pradofloxacin
thioglycerol
Prior art date
Application number
ARP180100319A
Other languages
English (en)
Inventor
Billian Patrick Dr
Heep Iris Dr
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of AR111032A1 publication Critical patent/AR111032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)

Abstract

Composiciones farmacéuticas en forma líquida que comprende pradofloxacina en una solución acuosa y ácido cítrico o tioglicerol como antioxidantes.
ARP180100319A 2017-02-13 2018-02-09 Composición líquida que contiene pradofloxacina AR111032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17155885 2017-02-13

Publications (1)

Publication Number Publication Date
AR111032A1 true AR111032A1 (es) 2019-05-29

Family

ID=58043920

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100319A AR111032A1 (es) 2017-02-13 2018-02-09 Composición líquida que contiene pradofloxacina

Country Status (24)

Country Link
US (2) US10780168B2 (es)
EP (1) EP3579820B1 (es)
JP (1) JP7257322B2 (es)
KR (1) KR102504435B1 (es)
CN (1) CN110248643B (es)
AR (1) AR111032A1 (es)
AU (1) AU2018217931B2 (es)
BR (1) BR112019016543A2 (es)
CL (1) CL2019002283A1 (es)
CO (1) CO2019008677A2 (es)
CR (1) CR20190370A (es)
DO (1) DOP2019000207A (es)
ES (1) ES2886088T3 (es)
IL (1) IL268329B (es)
MX (1) MX387370B (es)
PE (1) PE20191462A1 (es)
PH (1) PH12019501946B1 (es)
RU (1) RU2019128568A (es)
SG (1) SG11201907073TA (es)
TW (1) TWI778017B (es)
UA (1) UA124124C2 (es)
UY (1) UY37603A (es)
WO (1) WO2018146194A1 (es)
ZA (1) ZA201906037B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2985640T3 (es) 2019-02-13 2024-11-06 Debx Medical Holding B V Composiciones para eliminar tejidos necróticos o infectados de lesiones de la superficie corporal y de la cavidadbucal

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9612230A (pt) * 1995-12-21 1999-07-13 Pfizer Formulações de quinolona injetáveis
WO1997031001A1 (de) 1996-02-23 1997-08-28 Bayer Aktiengesellschaft Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19854355A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908448A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation D von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo[4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino incarbonsäure
JP4373649B2 (ja) * 2002-08-01 2009-11-25 ロート製薬株式会社 経口用液剤
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DK1757293T3 (da) * 2004-05-11 2012-10-22 Daiichi Sankyo Co Ltd Bh4-responsiv hyperphenylalaninæmi-medikamenter
AU2012202013A1 (en) * 2004-12-09 2012-05-03 Bayer Intellectual Property Gmbh Medicament for hygienic application inside the ear
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
JP4921750B2 (ja) * 2005-09-14 2012-04-25 株式会社日本点眼薬研究所 ピレノキシンまたは薬理学的に許容される塩を含有する懸濁性医薬組成物
DE102006010642A1 (de) 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
JP5624281B2 (ja) * 2009-04-21 2014-11-12 東亜薬品株式会社 光安定性に優れたキノロン系抗菌薬含有液体製剤
CN103830240B (zh) * 2012-11-27 2016-07-06 洛阳惠中兽药有限公司 一种氟喹诺酮药物组合物
CN102988286A (zh) * 2012-12-13 2013-03-27 江苏恒丰强生物技术有限公司 一种恩诺沙星注射液
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
AR105319A1 (es) * 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico

Also Published As

Publication number Publication date
BR112019016543A2 (pt) 2020-03-31
PE20191462A1 (es) 2019-10-16
ZA201906037B (en) 2025-10-29
RU2019128568A (ru) 2021-03-15
EP3579820B1 (en) 2021-04-28
ES2886088T3 (es) 2021-12-16
AU2018217931A1 (en) 2019-08-22
CN110248643A (zh) 2019-09-17
UY37603A (es) 2018-08-31
DOP2019000207A (es) 2019-08-30
KR102504435B1 (ko) 2023-02-27
EP3579820A1 (en) 2019-12-18
IL268329A (en) 2019-09-26
TWI778017B (zh) 2022-09-21
IL268329B (en) 2021-08-31
US10780168B2 (en) 2020-09-22
MX387370B (es) 2025-03-18
SG11201907073TA (en) 2019-08-27
CN110248643B (zh) 2023-11-24
US11617792B2 (en) 2023-04-04
TW201831184A (zh) 2018-09-01
NZ755854A (en) 2023-11-24
CA3053211A1 (en) 2018-08-16
UA124124C2 (uk) 2021-07-21
CO2019008677A2 (es) 2019-08-30
RU2019128568A3 (es) 2021-03-15
US20200376126A1 (en) 2020-12-03
US20200030449A1 (en) 2020-01-30
AU2018217931B2 (en) 2023-04-13
MX2019009572A (es) 2019-10-02
KR20190112733A (ko) 2019-10-07
CR20190370A (es) 2019-10-21
WO2018146194A1 (en) 2018-08-16
PH12019501946B1 (en) 2023-11-15
JP2020507570A (ja) 2020-03-12
JP7257322B2 (ja) 2023-04-13
PH12019501946A1 (en) 2020-06-01
CL2019002283A1 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CL2016001547A1 (es) Composiciones para el cuidado oral
MY179756A (en) Stabilized efinaconazole formulations
MX387604B (es) Formulaciones cannabinoides estables.
MX378273B (es) Compuestos activos hacia bromodominios.
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
AR098168A1 (es) Formulación estable de insulina glulisina
CO2017007316A2 (es) Formulación farmacéutica
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
SI3429559T1 (sl) Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
GEP20237486B (en) Formulations of copanlisib
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
CL2016000944A1 (es) Nueva formulación de ganadotropinas
CZ2014676A3 (cs) Aplikační směs pro zvýšení účinnosti antiseptik a/nebo dezinficiens, aplikační prostředek obsahující aplikační směs, a použití této směsi
DOP2019000207A (es) Composición líquida que contiene pradofloxacina
MX390441B (es) Formulaciones liquidas de fosfaplatino.
FI20155045A7 (fi) Havupuun pihka steriilin tulehduksen hoitamiseksi ja ennaltaehkäisemiseksi
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
UY34895A (es) Formulaciones estabilizadas de etanercept
UA116464U (uk) Протимікробний засіб

Legal Events

Date Code Title Description
FG Grant, registration